Ultravist 150 and Staphylococcal infection - a phase IV clinical study of FDA data

Summary:

Staphylococcal infection is found among people who take Ultravist 150, especially for people who are male, 60+ old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Ultravist 150 and have Staphylococcal infection. It is created by eHealthMe based on reports of 1,345 people who have side effects when taking Ultravist 150 from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On Jun, 16, 2022

1,345 people reported to have side effects when taking Ultravist 150.
Among them, 9 people (0.67%) have Staphylococcal infection.


What is Ultravist 150?

Ultravist 150 has active ingredients of iopromide. eHealthMe is studying from 1,345 Ultravist 150 users for its effectiveness, alternative drugs and more.

What is Staphylococcal infection?

Staphylococcal infection (an infection with staphylococcus bacteria) is found to be associated with 2,185 drugs and 1,783 conditions by eHealthMe.

Number of Ultravist 150 and Staphylococcal infection reports submitted per year:

Could Ultravist 150 cause Staphylococcal infection?

Time on Ultravist 150 when people have Staphylococcal infection *:

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Staphylococcal infection when taking Ultravist 150 *:

  • female: 0.0 %
  • male: 100 %

Age of people who have Staphylococcal infection when taking Ultravist 150 *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common drugs people take besides Ultravist 150 *:

  1. Propofol: 9 people, 100.00%
  2. Norfloxacin: 9 people, 100.00%
  3. Dimeticone: 9 people, 100.00%
  4. Tramadol Hydrochloride: 8 people, 88.89%
  5. Sorafenib: 8 people, 88.89%
  6. Nexavar: 1 person, 11.11%

Common side effects people have besides Staphylococcal infection *:

  1. Upper Gastrointestinal Haemorrhage (upper gastrointestinal bleeding): 9 people, 100.00%
  2. Pneumonia Bacterial (pneumonia associated with bacterial infection): 9 people, 100.00%
  3. Lower Gastrointestinal Haemorrhage (bleeding in the large intestine, rectum, or anus is called lower gi bleeding): 9 people, 100.00%
  4. Interstitial Lung Disease: 9 people, 100.00%
  5. Hepatic Failure (liver failure): 9 people, 100.00%
  6. Enterobacter Infection (infection caused by bacteria of the family enterobacteriaceae): 9 people, 100.00%
  7. Endocarditis (inflammation in heart muscle): 9 people, 100.00%
  8. Hepatic Encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure): 7 people, 77.78%
  9. Urine Output - Decreased: 1 person, 11.11%

Common conditions people have *:

  1. Hepatic Neoplasm Malignant (liver cancer): 9 people, 100.00%
  2. Abdominal Pain Upper: 9 people, 100.00%
  3. Sedation: 5 people, 55.56%

* Approximation only. Some reports may have incomplete information.

Do you take Ultravist 150 and have Staphylococcal infection?

Check whether Staphylococcal infection is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of Ultravist 150:

Staphylococcal infection treatments and more:

COVID vaccines that are related to Staphylococcal infection:

How severe was Staphylococcal infection and when was it recovered:

Expand to all the drugs that have ingredients of iopromide:

Common drugs associated with Staphylococcal infection:

All the drugs that are associated with Staphylococcal infection:

Common conditions associated with Staphylococcal infection:

All the conditions that are associated with Staphylococcal infection:

How the study uses the data?

The study uses data from the FDA. It is based on iopromide (the active ingredients of Ultravist 150) and Ultravist 150 (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: